

# Margaret I Liang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2026222/publications.pdf>

Version: 2024-02-01

15  
papers

135  
citations

1307594

7  
h-index

1199594

12  
g-index

16  
all docs

16  
docs citations

16  
times ranked

224  
citing authors

#	ARTICLE	IF	CITATIONS
1	Misoprostol and estradiol to enhance visualization of the transformation zone during cervical cancer screening: An integrative review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 269, 16-23.	1.1	2
2	Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2022, , .	1.4	0
3	Effect of misoprostol on type 3 transformation zone of the cervix among Cameroonian women. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100944.	0.6	1
4	Measuring Financial Distress and Quality of Life Over Time in Patients With Gynecologic Cancer—Making the Case to Screen Early in the Treatment Course. <i>JCO Oncology Practice</i> , 2021, 17, e1576-e1583.	2.9	15
5	Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 793-799.	1.4	11
6	The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?. <i>Gynecologic Oncology</i> , 2021, 160, 800-804.	1.4	10
7	Pathology findings among women with alterations in uterine bleeding patterns in cameroon. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100821.	0.6	0
8	Extensive financial hardship among gynecologic cancer patients starting a new line of therapy. <i>Gynecologic Oncology</i> , 2020, 156, 271-277.	1.4	32
9	Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. <i>Journal of Surgical Oncology</i> , 2019, 120, 779-785.	1.7	7
10	Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1156-1163.	2.5	4
11	Perspectives on Conversations About Costs of Cancer Care of Breast Cancer Survivors and Cancer Center Staff. <i>Annals of Internal Medicine</i> , 2019, 170, S54.	3.9	19
12	Emerging From the Haze: A Pilot Study Evaluating Feasibility of a Psychoeducational Intervention to Improve Cancer-Related Cognitive Impairment in Gynecologic Cancer Survivors. <i>Journal of Palliative Care</i> , 2019, 34, 32-37.	1.0	7
13	Financial toxicity — An overlooked side effect. <i>Gynecologic Oncology</i> , 2018, 150, 3-6.	1.4	17
14	Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman. <i>Gynecologic Oncology</i> , 2018, 151, 6-9.	1.4	0
15	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e1030-e1039.	2.5	10